Aditya Bagrodia is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, where he is the Dedman Family Scholar in Clinical Care.
Dr. Bagrodia holds a bachelor of science degree from Rhodes College. While earning a medical degree with highest honors at the University of Tennessee Health Sciences Center, he was awarded a Doris Duke Clinical Research Fellowship in clinical research at UT Southwestern Medical Center.
After graduating from residency in urology at UT Southwestern, he completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center, where he received an American Urological Association Urology Care Foundation Research Scholars Grant.
Dr. Bagrodia’s clinical practice is comprised all urologic malignancies including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.
Dr. Bagrodia’s clinical and research focus centers on patients with germ cell tumors (most commonly testicular cancer). His laboratory focuses on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors as well as to identify novel biomarkers to recognize occult metastatic disease. The Bagrodia lab also conducts experiments in cell lines, zebrafish germ cell tumor models, and mice to understand the biologic implications of genetic alterations that are seen exclusively among patients with cisplatin-resistance disease. He is actively working on molecular biomarkers to identify minimal residual disease burden. On the clinical side, Dr Bagrodia is actively involved with understanding and overcoming unique socioepidemiologic considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials at UT Southwestern (NCT03426865, NCT02537548).
Dr. Bagrodia has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He is funded through competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT), intramural grants, and NIH-funding.
He is the principal author or co-author of more than 100 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. He is also a reviewer for many of these publications, as well as the British Journal of Urology, the Journal of Clinical Pathology, and Annals of Surgical Oncology.